AstraZeneca’s cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.

A first-in-class drug from Amgen based on a tumor-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months.   The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness. The European […]